University leaders, clinicians and industry partners recently gathered to celebrate the opening of the Imaging Research & Development Center on UC’s medical campus.
Tirzepatide met the primary endpoint of non-inferiority versus dulaglutide, with an 8% lower rate of MACE events included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight.
Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful.